Digests

May 2026

This Month in Ovarian Cancer Research

May 2026 ovarian cancer research featured a phase 1/2 trial combining a survivin-targeting vaccine with pembrolizumab showing a 23% response rate in recurrent disease, real-world HRD testing data revealing uneven access across Europe, and a Nature Communications study finding ascites fluid actively shields cancer cells from cell death through a potentially targetable mechanism.

May 2026

This Month in Cervical Cancer Research

May 2026 cervical cancer research identified CD155 as a new immunotherapy target for tumors unresponsive to pembrolizumab, while prevention-focused studies from Morocco documented near-total public unawareness of its national HPV vaccination program alongside hesitancy driven largely by peer influence and inadequate provider engagement.

May 2026

This Month in Uterine Cancer Research

May 2026 uterine cancer research clarified that all mismatch repair-deficient tumors share equally favorable prognosis regardless of which gene is affected, an NHS cohort study found 99% of HRT users investigated for unscheduled bleeding did not have cancer, and preclinical research identified a molecular mechanism driving progesterone resistance in fertility-sparing treatment.

May 2026

This Month in Vaginal & Vulvar Cancer Research

May 2026 vulvar cancer research found most patients prioritize survival over reduced surgical side effects from sentinel node biopsy, challenging clinical assumptions. Vaginal cancer research showed combination photodynamic therapy outperformed single-treatment VaIN management, while both digests reinforced HPV vaccination's importance for prevention.